Rimonabant acomplia
Only two prescription weight-loss drugs are on the market, and neither has had much success. He’s on the advisory board rimonabant acomplia of Sanofi-Aventis. Few safe and effective medications are available for obesity, but new understanding of the physiologic regulation of food intake and calorie storage have led to the development of therapies targeting the endocannabinoid system. Participants also were required to have experienced less than 11-lb (5-kg) variation in body weight in the three months before the study, and to be free from significant cardiovascular, pulmonary, hepatic, renal, neurologic, psychiatric, and endocrine disease, including diabetes. Addressing associated risk factors is a rimonabant acomplia novel aspect. Approval in America, the world’s biggest drugs market, is crucial. OBESITY TREATMENTUnder development by Sanofi-Synthelabo, rimonabant (Acomplia) shows promise as both a weight-loss and smoking-cessation drug. Basically, it appears to help break the connection between an activity like smoking and the rewarding feeling it causes in the brain. The indications for which it is approved are also important. Medications blocking receptors in this system have Rimonabant acomplia the potential to contribute significantly to antiobesity therapy. The percentage of patients with 10 percent or more weight loss was significantly greater in the 20-mg group (27. 4 percent) than the placebo group (7. 3 percent) but not in the 5-mg group (10. 1 percent). Xavier Pi-Sunyer, M. , a professor of medicine at Columbia University in New York City, who led one of Rimonabant acomplia the studies. Only 61 percent of participants completed the one-year follow-up: 379 (62. 7 percent) in the 5-mg group, 363 (60. 6 percent) in rimonabant acomplia the 20-mg group, and 178 (58. 4 percent) in the placebo group. If only those patients who completed the study were considered, these figures rose to 39 percent in the 20-mg rimonabant acomplia group, 12. Rimonabant acomplia 4 percent in the placebo group, and 15. Rimonabant acomplia 3 percent in the 5-mg group. Jeffrey Friedman, an obesity researcher at Rockefeller University, is the first in what I think will be a wave of rational therapies that attack what has recently been learned about how eating is controlled. We base our price target of $94. 48 on a discounted cash flow valuation adjusted for the risk of a successful Plavix patent challenge and flat-tail products. We highlight that the RIO-diabetes patient population was limited to rimonabant acomplia patients given only one prior treatment with one hypoglycemic agent. Merck expects FDA action on the New Drug Application for MK-0431A by the end of March 2007. And by the way, those who take it will end up with higher levels of HDL, the good cholesterol. In studies of more than 6,600 people, the still-experimental drug helped people lose and maintain a weight loss of 19 pounds over two years while people on rimonabant acomplia a placebo pill maintained only a 5-pound weight loss. For those who remain wary of medications for weight loss, the study offers validation of the old-fashioned advice about lifestyle rimonabant acomplia as well as the hope that new therapies might be available in the future. Donald Hensrud, M. , editor in chief of Mayo Clinic Healthy Weight for EveryBody (Mayo Foundation for Medical Education and Research, 2005), weighs in on what really works for weight loss. Rimonabant acomplia the timing is auspicious.
